Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kayla Hess

Physician Assistant White Oak, PA Physician Assistant

NPI 1497325054 CMS profile 11247052

1220 Lincoln Way Ste 101, White Oak, PA 15131

Open in the dashboard

General payments

$10,330

413 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kayla Hess of White Oak, PA is reported in the CMS Open Payments database as having received $10,330 across 413 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,553 110
2024 General $3,565 145
2023 General $2,004 90
2022 General $1,646 50
2021 General $561 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kayla Hess
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kayla Hess were reported at $2,553. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kayla Hess Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $561 $132 $37–$438 $132
2022 $1,646 $155 $48–$522 $149
2023 $2,004 $167 $52–$557 $160
2024 $3,565 $178 $55–$600 $164
2025 $2,553 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,119 62 payments
  2. Regeneron Healthcare Solutions, Inc. $1,060 27 payments
  3. Genzyme Corporation $859 32 payments
  4. Journey Medical Corporation $809 7 payments
  5. LEO Pharma Inc. $799 41 payments
  6. Galderma Laboratories, L.P. $729 34 payments
  7. Novartis Pharmaceuticals Corporation $679 18 payments
  8. Sun Pharmaceutical Industries Inc. $651 33 payments
  9. Janssen Biotech, Inc. $603 29 payments
  10. E.R. Squibb & Sons, L.L.C. $561 24 payments
  11. Other $2,460 106 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,812 406 payments
  2. Education $518 7 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,246 45 payments
  2. DUPIXENT Inflammation And Immunology $660 18 payments
  3. TREMFYA $603 29 payments
  4. ADBRY $561 35 payments
  5. SOTYKTU $561 24 payments
  6. RINVOQ $539 35 payments
  7. DUPIXENT Immunology And Inflammation $500 10 payments
  8. Bimzelx $426 17 payments
  9. SKYRIZI $420 17 payments
  10. Winlevi $367 20 payments
  11. Other $4,428 218 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,284

Median for Physician Assistant: 241

Drug cost

$424,568

Median for Physician Assistant: $4,110

Branded share of claims

8.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 41 $163,718
Cosentyx (2 Syringes) Secukinumab Brand 15 $113,969
Otezla Apremilast Brand 17 $71,272
Opzelura Ruxolitinib Phosphate Brand 15 $27,833
Zoryve Roflumilast Brand 12 $9,608
Tacrolimus Generic 78 $8,390
Ketoconazole Generic 347 $6,570
Clobetasol Propionate Generic 97 $5,008
Calcipotriene Generic 36 $4,353
Metronidazole Generic 66 $2,676

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$75,886

Medicare's payments for the services billed

Medicare patients

707

Average age 75

Services billed

3,450

373 women, 334 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 31%
Ischemic heart disease 26%
Chronic kidney disease 22%
Atrial fibrillation 18%
COPD 17%
Depression 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $380
$380 — —
DUPIXENT
  • GENZYME CORPORATION $155
  • Regeneron Healthcare Solutions, Inc. $89
  • SANOFI-AVENTIS U.S. LLC $87
$330 41 —
ADBRY
  • LEO Pharma Inc. $328
$328 — —
Bimzelx
  • UCB, Inc. $311
$311 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $302
$302 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

413 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record